Brazilian Journal of Infectious Diseases ()

Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil

  • R. Focaccia,
  • D.C.M. Baraldo,
  • M.L.G. Ferraz,
  • A.L.C. Martinelli,
  • F.J. Carrilho,
  • F.L. Gonçales Jr.,
  • M.L.A. Pedroso,
  • H.S.M. Coelho,
  • M.A. Lacerda,
  • C.E. Brandão,
  • A.A. Mattos,
  • L.G.C. Lira,
  • I. Zamin Jr.,
  • J.O.P. Pinheiro,
  • C.V. Tovo,
  • C.T. Both,
  • J.A.S. Soares,
  • S. Dittrich

DOI
https://doi.org/10.1590/S1413-86702004000500003
Journal volume & issue
Vol. 8, no. 5
pp. 348 – 355

Abstract

Read online

Hepatitis C virus (HCV) infection is a serious public health problem, since 80% to 85% of HCV carriers develop a persistent infection that can progress into liver cirrhosis and hepatocarcinoma. Considering that the response of hepatitis C patients to combination therapy with interferon and ribavirin depends on HCV characteristics as well as on host features, we made a retrospective analysis of demographic and anthropometrical data and HCV genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. The medical records of 4,996 patients were reviewed, 81% from public and 19% from private institutions. Patients' median age was 46 years, and there was a higher prevalence of male (62%) and white patients (80%). The analysis of HCV-infecting strains showed a predominance of genotype 1 (64%) over genotypes 2 and 3. The patients' mean weight was 70.6 kg, and 65% of the patients weighed less than 77kg. Overweight and obesity were observed in 37.8% and 13.6% of the patients, respectively. Since a body weight of 75 kg or less has been considered an independent factor that significantly increases the odds of achieving a sustained virological response, the Brazilian population seems to have a more favorable body weight profile to achieve a sustained response than the American and European populations. The finding that 65% of chronic hepatitis C patients have a body weight of 77 kg or less may have a positive pharmacoeconomic impact on the treatment of genotype 1 HCV patients with weight-based doses of peginterferon.

Keywords